There is a substantial burden, unawareness, and undertreatment of several systemic comorbidities—particularly cardiovascular and psychiatric—in patients with HS.
Even with care in specialty clinics, LDL-C persists above target levels in more than half of patients with familial hypercholesterolemia.
Researchers used using observational administrative claims data from the Optum Research Database to retrospectively examine the real-world effect of elevated triglyceride levels on cardiovascular outcomes and medical cost.
Compared with usual care, a polypill regimen led to greater reductions in systolic blood pressure and low-density lipoprotein cholesterol level in socioeconomically vulnerable minority patients.
Full detailed data will be presented at the AHA Scientific Sessions in Philadelphia in November 2019.
Investigators examined both incidence and predictive factors of subclinical and clinical atherosclerosis in patients with rheumatoid arthritis.
Investigators analyzed whether high LDL-C causally relates to risk for retinopathy, neuropathy, chronic kidney disease, and peripheral artery disease in the general population.
Researchers evaluated how feasible, safe, and effective evolocumab is at lowering low-density lipoprotein cholesterol when initiated in patients hospitalized with acute coronary syndrome.
Greater exposure to the World Trade Center (WTC) site is associated with increased long-term cardiovascular disease risk.
Results demonstrated inclisiran to have met both primary end points with a favorable safety profile.
There are modest associations between higher lipid levels and circulating leukocyte counts in humans.